Laboratory analyses showed that the patient who developed AML had significant chromosomal abnormalities and mutations in the RUNX1 and PTPN11 genes typically associated with the development of the ...

14 relapsed and refractory AML patients who previously failed venetoclax ... In terms of specific mutations, 6 patients had ASXL1, 5 had RUNX1 and 3 had TP53. The median age was 71 (range 35-89 ...

SELLAS Life Sciences (SLS) announced Cohort 3 data from the ongoing Phase 2 trial of SLS009, a highly selective CDK9 inhibitor, in ...

In the subgroup of patients with myelomonocytic AML, 75% of patients responded (3 out of 4). Among patients with mutation ASXL1, 4/6 (67%) responded; among those with RUNX1 3/5 (60%) responded ...

In the subgroup of patients with myelomonocytic AML, 75% of patients responded (3 out of 4). Among patients with mutation ASXL1, 4/6 (67%) responded; among those with RUNX1 3/5 (60%) responded ...